Stock listing
NASDAQ:KLRS Kalaris Therapeutics, Inc. Stock
Home listing (NASDAQ) of Kalaris Therapeutics, Inc.
Follow Kalaris Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:KLRS
$1.28 USD -0.09 (-6.6%)
Close on Nov 20, 2026
- Day range
- $1.25 – $1.37 USDNov 20, 2026
- Volume
- 37,986 sharesNov 20, 2026
- Market cap
- $30.47M USDAt the close on Nov 20, 2026 · price × 23.80M shares outstanding
- 52-week range
- $1.25 – $11.88 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $201,311 USDMedian day 58,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:KLRS · Home | $1.28 USD | -0.09 (-6.6%) | 37,986 | $1.31 | $1.37 | $1.25 | $1.37 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KLRS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.28 | -0.09 | -6.6% | $1.31 | $1.37 | $1.25 | 37,986 | |
| $1.37 | -0.06 | -4.2% | $1.43 | $1.495 | $1.35 | 53,156 | |
| $1.43 | -0.03 | -2.1% | $1.46 | $1.55 | $1.33 | 252,572 | |
| $1.46 | -0.115 | -7.3% | $1.58 | $1.65 | $1.41 | 157,336 | |
| $1.575 | -0.085 | -5.1% | $1.64 | $1.696 | $1.55 | 41,002 | |
| $1.66 | -0.24 | -12.6% | $1.90 | $1.945 | $1.65 | 200,281 | |
| $1.90 | +0.03 | +1.6% | $1.90 | $1.98 | $1.845 | 66,623 | |
| $1.87 | -0.43 | -18.7% | $2.20 | $2.375 | $1.80 | 81,438 | |
| $2.30 | -0.12 | -5.0% | $2.49 | $2.50 | $2.28 | 72,759 | |
| $2.42 | +0.06 | +2.5% | $2.36 | $2.66 | $2.34 | 197,850 | |
| $2.36 | +0.34 | +16.8% | $2.01 | $2.46 | $1.94 | 175,470 | |
| $2.02 | -0.03 | -1.5% | $2.029 | $2.14 | $2.01 | 28,386 | |
| $2.05 | +0.05 | +2.5% | $2.09 | $2.14 | $2.03 | 19,222 | |
| $2.00 | -0.03 | -1.5% | $2.06 | $2.06 | $1.92 | 59,274 | |
| $2.03 | -0.10 | -4.7% | $1.98 | $2.08 | $1.965 | 60,195 | |
| $2.13 | +0.12 | +6.0% | $2.05 | $2.161 | $2.05 | 23,166 | |
| $2.01 | +0.15 | +8.1% | $1.86 | $2.02 | $1.86 | 47,608 | |
| $1.86 | +0.06 | +3.3% | $1.78 | $1.875 | $1.78 | 50,126 | |
| $1.80 | -0.07 | -3.7% | $1.90 | $1.90 | $1.78 | 36,033 | |
| $1.87 | -0.12 | -6.0% | $1.99 | $1.99 | $1.87 | 25,400 | |
| $1.99 | -0.03 | -1.5% | $2.01 | $2.04 | $1.95 | 43,400 | |
| $2.02 | -0.05 | -2.4% | $2.00 | $2.182 | $1.95 | 84,400 | |
| $2.07 | +0.16 | +8.4% | $1.90 | $2.10 | $1.90 | 51,400 | |
| $1.91 | -0.09 | -4.5% | $2.04 | $2.04 | $1.867 | 271,500 | |
| $2.00 | -0.19 | -8.7% | $2.25 | $2.292 | $2.00 | 58,400 | |
| $2.19 | +0.06 | +2.8% | $2.20 | $2.225 | $2.10 | 57,000 | |
| $2.13 | -0.10 | -4.5% | $2.22 | $2.23 | $2.11 | 21,000 | |
| $2.23 | -0.03 | -1.3% | $2.27 | $2.295 | $2.20 | 73,300 | |
| $2.26 | -0.10 | -4.2% | $2.37 | $2.37 | $2.22 | 122,100 | |
| $2.36 | -0.14 | -5.6% | $2.46 | $2.55 | $2.36 | 104,400 | |
| $2.50 | -0.06 | -2.3% | $2.60 | $2.60 | $2.35 | 110,000 | |
| $2.56 | -0.10 | -3.8% | $2.59 | $2.693 | $2.53 | 74,100 | |
| $2.66 | -0.17 | -6.0% | $2.90 | $2.93 | $2.61 | 103,400 | |
| $2.83 | +0.13 | +4.8% | $2.72 | $2.89 | $2.58 | 27,400 | |
| $2.70 | -0.15 | -5.3% | $2.90 | $2.90 | $2.51 | 235,900 | |
| $2.85 | -0.04 | -1.4% | $2.88 | $2.89 | $2.76 | 58,600 | |
| $2.89 | -0.01 | -0.3% | $2.87 | $2.97 | $2.75 | 102,600 | |
| $2.90 | +0.055 | +1.9% | $2.84 | $2.91 | $2.835 | 51,800 | |
| $2.845 | -0.075 | -2.6% | $2.91 | $2.97 | $2.81 | 92,800 | |
| $2.92 | -0.15 | -4.9% | $3.024 | $3.09 | $2.91 | 49,300 | |
| $3.07 | -0.05 | -1.6% | $3.13 | $3.162 | $3.02 | 33,600 | |
| $3.12 | -0.12 | -3.7% | $3.20 | $3.21 | $3.12 | 24,000 | |
| $3.24 | -0.005 | -0.2% | $3.225 | $3.285 | $3.16 | 29,100 | |
| $3.245 | +0.045 | +1.4% | $3.20 | $3.30 | $3.09 | 88,600 | |
| $3.20 | +0.04 | +1.3% | $3.18 | $3.23 | $3.04 | 234,400 | |
| $3.16 | -0.02 | -0.6% | $3.20 | $3.27 | $3.13 | 43,300 | |
| $3.18 | -0.02 | -0.6% | $3.15 | $3.25 | $3.10 | 61,700 | |
| $3.20 | -0.10 | -3.0% | $3.35 | $3.355 | $3.20 | 109,400 | |
| $3.30 | -0.08 | -2.4% | $3.41 | $3.445 | $3.25 | 57,600 | |
| $3.38 | +0.08 | +2.4% | $3.39 | $3.44 | $3.27 | 95,100 | |
| $3.30 | -0.17 | -4.9% | $3.55 | $3.66 | $3.30 | 60,700 | |
| $3.47 | -0.16 | -4.4% | $3.66 | $3.68 | $3.45 | 83,000 | |
| $3.63 | -0.27 | -6.9% | $3.88 | $3.90 | $3.60 | 100,700 | |
| $3.90 | -0.04 | -1.0% | $3.91 | $3.95 | $3.82 | 23,900 | |
| $3.94 | +0.04 | +1.0% | $3.97 | $4.04 | $3.905 | 40,000 | |
| $3.90 | -0.02 | -0.5% | $3.97 | $4.135 | $3.90 | 16,400 | |
| $3.92 | -0.12 | -3.0% | $3.96 | $4.00 | $3.86 | 62,300 | |
| $4.04 | +0.01 | +0.2% | $3.99 | $4.04 | $3.83 | 19,600 | |
| $4.03 | -0.07 | -1.7% | $4.12 | $4.15 | $3.89 | 52,600 | |
| $4.10 | +0.02 | +0.5% | $4.08 | $4.19 | $4.00 | 104,900 | |
| $4.08 | -0.12 | -2.9% | $4.24 | $4.31 | $3.99 | 28,200 | |
| $4.20 | +0.10 | +2.4% | $4.04 | $4.25 | $4.04 | 26,300 | |
| $4.10 | -0.05 | -1.2% | $4.13 | $4.19 | $3.94 | 51,400 | |
| $4.15 | +0.03 | +0.7% | $4.10 | $4.305 | $3.99 | 81,200 | |
| $4.12 | -0.05 | -1.2% | $4.20 | $4.20 | $3.97 | 50,200 |
Splits
1 split · NASDAQ:KLRS · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-23 | Consolidation |
- Ticker
- NASDAQ:KLRS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 56 slides
Latest news
Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 10, 2026
Closed $1.87 (-18.7%) on Nov 10, 2026
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Aug 31, 2026
Closed $4.04 (+0.2%) on Aug 31, 2026
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
Jul 20, 2026
Closed $4.00 (-8.7%) on Jul 20, 2026
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Jul 17, 2026
Closed $4.38 (-5.0%) on Jul 17, 2026
Kalaris Appoints Laurie Keating to Board of Directors
Jul 6, 2026
Closed $4.83 (+3.9%) on Jul 7, 2026
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
Jun 23, 2026
Closed $4.47 (+1.6%) on Jun 23, 2026
Kalaris to Present at Clinical Trials at the Summit 2026
Jun 12, 2026
Closed $4.33 (-0.7%) on Jun 12, 2026
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
May 12, 2026
Closed $4.79 (+1.3%) on May 12, 2026
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
Mar 17, 2026
Closed $8.52 (-3.3%) on Mar 17, 2026
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
Jan 28, 2026
Closed $9.20 (-2.6%) on Jan 29, 2026
Kalaris Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 49 in all · newest Nov 10, 2026 · oldest 2022
- Decks
- 8 decks · latest September 2026
Where Kalaris Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:KLRS · Home listing · This page | NASDAQ | United States | USD |
| BOATS:KLRS | BOATS | United States | USD |
Valuation
Price/book 0.6× against a median of 3.3×: 3rd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$51.05M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.47
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Kalaris Therapeutics, Inc. · NASDAQ:KLRS | US$30.47M | −US$51.05M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.47 |
| Molecure SA · GPW:MOC | US$31.64M | US$29.58M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| Isofol Medical AB · OMXSTO:ISOFOL | US$31.09M | US$19.84M | n/a | n/a | n/a | 3.3× | n/a | 0.0× | n/a |
| Sareum Holdings plc · LSE:SAR | US$31.04M | US$27.79M | n/a | n/a | n/a | 19.9× | n/a | 0.0× | n/a |
| Filana Therapeutics, Inc. · NASDAQ:FLNA | US$30.98M | −US$16.01M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.25 |
| Caribou Biosciences, Inc. · NASDAQ:CRBU | US$30.71M | −US$37.75M | n/a | −4.0× | n/a | 0.4× | n/a | 0.3× | 1.87 |
| Avecho Biotechnology Limited · ASX:AVE | US$30.70M | US$26.48M | n/a | 32.3× | n/a | 24.3× | −356.8% | 0.1× | n/a |
| Pacific Software, Inc. · OTC:PFSF | US$29.86M | US$38.10M | n/a | n/a | n/a | n/a | n/a | n/a | 1.57 |
| NextCure, Inc. · NASDAQ:NXTC | US$29.53M | US$20.81M | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.85 |
| NurExone Biologic Inc · TSXV:NRX | US$29.53M | US$28.52M | n/a | n/a | n/a | 23.3× | n/a | 0.0× | 0.00 |
| BioHarvest Sciences, Inc. · NASDAQ:BHST | US$29.47M | US$34.54M | n/a | 1.0× | n/a | 1.8× | −34.7% | 1.0× | 0.43 |
| Median of the others | US$30.71M | US$27.13M | 1.0× | 3.3× | −195.7% | 0.0× | 1.41 |
Forecasts
5 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 18.80 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.92 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Andrew Oxtoby | CEO & Director |
| Liisa Bayko | CFO |
| Jill Porter | SVP CMC |
| Kristine Curtiss | SVP Clinical |
| Nancy Davis | VP Clinical Operations |
| Mike Dybbs | Director & Co-founder |
| Napoleone Ferrara | Director & Co-Founder |
| Srinivas Akkaraju | Director & Co-founder |
Board
| Director | Role |
|---|---|
| Andrew Oxtoby | CEO & Director |
| Anthony Adamis | Director |
| Laurie Keating | Director |
| Leone Patterson | Director |
| Mike Dybbs | Director & Co-founder |
| Napoleone Ferrara | Director & Co-Founder |
| Srinivas Akkaraju | Director & Co-founder |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | −18.7% |
| Q2 2026 | Aug 11, 2026 · Before open | +0.8% |
| Q1 2026 | May 12, 2026 · Before open | +1.3% |
| Q4 2025 | Mar 17, 2026 | −14.5% |
| Q3 2025 | Nov 12, 2025 · Before open | −2.2% |
| Q2 2025 | Aug 13, 2025 · Before open | −8.4% |
| Q1 2025 | May 14, 2025 · Before open | +4.0% |
| Q4 2024 | Feb 12, 2025 | +1.0% |
| Q3 2024 | Nov 29, 2024 | −1.9% |
| Q2 2024 | Aug 1, 2024 | +3.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 | −1.5% |
| Q4 2023 | Feb 8, 2024 | +7.1% |
| Q3 2023 | Nov 2, 2023 | +9.1% |
| Q2 2023 | Aug 3, 2023 | +3.0% |
| Q1 2023 | May 4, 2023 | +14.3% |
| Q4 2022 | Feb 15, 2023 | −6.1% |
| Q3 2022 | Nov 3, 2022 | +0.8% |
| Q2 2022 | Aug 4, 2022 | +33.6% |
| Q1 2022 | May 5, 2022 | +0.4% |
| Q4 2021 | Feb 10, 2022 | +2.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 56 slides | September 2026 |
| Investor Presentation (July 2026) | Investor deck | 57 slides | Jul 17, 2026 |
| Investor Presentation (March 2026) | Investor deck | 58 slides | Mar 9, 2026 |
| Technical Presentation (December 2025) | Technical | 30 slides | Dec 17, 2025 |
| Technical Presentation (December 2025) | Technical | 41 slides | December 2025 |
| American Society of Retina Specialists Annual Meeting (December 2025) | Conference | 11 slides | December 2025 |
| Allovir — Merger or Acquisition (December 2024) | Merger or acquisition | 39 slides | Dec 9, 2024 |
| Merger or Acquisition (November 2024) | Merger or acquisition | 39 slides | Nov 25, 2024 |
Financings
| Raise | Date |
|---|---|
| Private placement of common stock and pre-funded warrants Announced: about US$50M · US$10 a share · Morgan Stanley +2 Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), William Blair Buyers: ADAR1 Capital Management; Coastlands Capital; Invus; RTW Investments; Samsara BioCapital; Woodline Partners LP Use of proceeds: Advance clinical development of TH103 for neovascular AMD, working capital and general corporate purposes | Dec 17, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Allovir, Inc. Priced at US$17.00 a share on Jul 29, 2020.
- Price
- US$17.00 a share
- Shares offered
- 16,250,000 shares of common stock
- Offering size
- US$276.3 million
- Underwriters' option
- Up to 2,437,500 more shares
- Underwriters
- MORGAN STANLEY, J.P. MORGAN, SVB LEERINK, PIPER SANDLER · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 3, 2020 |
| Filed publicly | Jul 6, 2020 |
| Amended once | Jul 23, 2020 |
| Shares registered with an exchange | Jul 27, 2020 |
| Declared effective by the SEC | Jul 29, 2020 |
| Final prospectus, with the price | Jul 30, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 30, 2020 |
| S-1MEF · Registration of more shares for the same offering | Jul 30, 2020 |
| EFFECT · Notice that a registration is effective | Jul 29, 2020 |
| CERT · Exchange's certificate of listing | Jul 29, 2020 |
| 8-A12B/A · Registration of shares for listing on an exchange, amended | Jul 29, 2020 |
| CORRESP · Letter to the SEC | Jul 28, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 27, 2020 |
| CORRESP · Letter to the SEC | Jul 27, 2020 |
| CORRESP · Letter to the SEC | Jul 27, 2020 |
| CORRESP · Letter to the SEC | Jul 27, 2020 |
All 20 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Jul 24, 2020 |
| CORRESP · Letter to the SEC | Jul 23, 2020 |
| S-1/A · Registration statement, amended | Jul 23, 2020 |
| CORRESP · Letter to the SEC | Jul 20, 2020 |
| CORRESP · Letter to the SEC | Jul 17, 2020 |
| UPLOAD · Letter from the SEC | Jul 14, 2020 |
| CORRESP · Letter to the SEC | Jul 6, 2020 |
| S-1 · Registration statement | Jul 6, 2020 |
| UPLOAD · Letter from the SEC | Jun 30, 2020 |
| DRS · Draft registration statement | Jun 3, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 30, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 165.0K | 1.14M | ||
| Cost of revenue | 13.0K | 1.12M | 73.0K | |||||
| Gross profit | -13.0K | -1.12M | -73.0K | |||||
| Research and development | 30.8M | 45.0M | 133.1M | 118.9M | 120.7M | 49.7M | 16.2M | 1.70M |
| Selling, general and administrative | 15.4M | 6.69M | 1.76M | 2.24M | ||||
| Operating income | -46.2M | -51.7M | -199.9M | -171.2M | -169.8M | -71.3M | -26.7M | -3.60M |
| Depreciation and amortization | 13.0K | 0 | 398.0K | 723.0K | 189.0K | 73.0K | 19.0K | |
| EBITDA | -46.1M | -51.7M | -199.5M | -170.5M | -169.6M | -71.2M | -26.7M | |
| Interest expense | 1.44M | 2.70M | 687.0K | 235.0K | ||||
| Income before tax | -43.4M | -69.2M | -190.5M | -169.0M | -171.0M | -69.8M | -23.8M | -2.43M |
| Income tax | 0 | 0 | -126.0K | -265.0K | 1.01M | |||
| Net income | -43.4M | -69.2M | -190.4M | -168.7M | -172.0M | -69.8M | -23.8M | -2.43M |
| Earnings per share, basic | -2.85 | -51.77 | -42.09 | -2.20 | -2.74 | -2.59 | -18.54 | -0.86 |
| Earnings per share, diluted | -2.85 | -51.77 | -42.09 | -2.20 | -2.74 | -2.59 | -18.54 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 98.1M | 1.64M | 90.1M | 106.1M | 201.7M | 122.7M | 61.1M | 25.0M |
| Short-term investments | 19.9M | 0 | 93.8M | 127.7M | 46.5M | 233.7M | 65.0M | |
| Receivables | 50.0K | 450.0K | 560.0K | 302.0K | ||||
| Current assets | 118.8M | 2.61M | 187.6M | 243.1M | 253.3M | 361.3M | 127.3M | 25.3M |
| Property, plant and equipment | 930.0K | 1.55M | 812.0K | 350.0K | ||||
| Total assets | 121.7M | 6.16M | 190.8M | 277.1M | 286.6M | 370.8M | 139.4M | 25.3M |
| Accounts payable | 1.28M | 1.56M | 6.76M | 3.00M | 8.36M | 963.0K | 630.0K | 153.0K |
| Current liabilities | 9.71M | 24.7M | 28.4M | 24.3M | 37.9M | 12.3M | 9.11M | 3.74M |
| Long-term debt | 3.25M | |||||||
| Total debt | 1.45M | 3.25M | 30.1M | 8.69M | 11.8M | |||
| Total liabilities | 42.9M | 56.8M | 45.0M | 52.6M | 61.3M | 17.8M | 17.8M | 3.74M |
| Shareholders' equity | 78.8M | -96.6M | -45.0M | 224.5M | 225.3M | 353.1M | -51.5M | 21.6M |
| Shares outstanding | 22.9M | 1.36M | 4.96M | 93.1M | 63.6M | 61.9M | 2.10M | 2.83M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -38.4M | -20.7M | -124.5M | -142.1M | -106.3M | -60.8M | -20.2M | 1.94M |
| Capital spending | -200.0K | 0 | 0 | 0 | -26.0K | -235.0K | -339.0K | 0 |
| Free cash flow | -38.6M | -67.7M | -14.1M | -9.78M | -106.3M | -61.0M | -20.5M | 1.94M |
| Cash from investing | -19.7M | 95.0M | 38.0M | -80.5M | 186.0M | -169.5M | -64.6M | |
| Cash from financing | 155.0M | 19.1M | 70.5M | 127.0M | 232.0K | 292.0M | 120.9M | 22.9M |
| Share buybacks | -10.0M | |||||||
| Change in cash | 96.9M | -1.53M | -16.0M | -95.6M | 79.9M | 61.6M | 36.1M | 25.0M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 3, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 3 · Initial statement of ownership | Jul 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 20, 2026 | Management or board change | SEC |
| 8-K · Current report | Jul 17, 2026 | Current report | SEC |
| 8-K · Current report | Jul 6, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 4, 2026 | Meeting outcome | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 22, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 14, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 14, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Apr 13, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Apr 13, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 10, 2026 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Apr 9, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 9, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 8, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 8, 2026 | Other filings | SEC |
| S-3 · Registration statement | Apr 3, 2026 | Offer document | SEC |
| S-3 · Registration statement | Apr 3, 2026 | Offer document | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 17, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 17, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 17, 2026 | Results | SEC |
| 8-K · Current report | Mar 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 22, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 18, 2025 | Material contract | SEC |
| 8-K · Current report | Dec 17, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 3, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Jul 1, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jul 1, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 1, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 20, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jun 4, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 8-K · Current report | Apr 16, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 4, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 27, 2025 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Mar 26, 2025 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Mar 25, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Mar 25, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 20, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 18, 2025 | Results | SEC |
| 8-K · Current report | Mar 12, 2025 | Management or board change | SEC |
| 10-K · Annual report | Mar 7, 2025 | Annual report | SEC |
| 424B3 · Prospectus | Feb 28, 2025 | Offer document | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 24, 2025 | Other filings | SEC |
| SEC STAFF LETTER | Feb 19, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Feb 11, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Feb 10, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 6, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 3, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | Feb 3, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jan 28, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 24, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 17, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | Jan 17, 2025 | Offer document | SEC |
| 425 | Jan 15, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 15, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 10, 2025 | Other filings | SEC |
| 425 | Jan 10, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 10, 2025 | Current report | SEC |
| 425 | Jan 10, 2025 | Other filings | SEC |
| SEC STAFF LETTER | Jan 10, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 10, 2025 | Meeting outcome | SEC |
| UPLOAD · Letter from the SEC | Jan 6, 2025 | Other filings | SEC |
| 425 | Dec 20, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 20, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Dec 11, 2024 | Insider trade | SEC |
| S-4 · Registration statement | Dec 9, 2024 | Offer document | SEC |
| 425 | Dec 6, 2024 | Other filings | SEC |
| DEF 14A · Proxy statement | Dec 6, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Nov 26, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 19, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 19, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 19, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 19, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 425 | Nov 8, 2024 | Other filings | SEC |
| 425 | Nov 8, 2024 | Other filings | SEC |
| 425 | Nov 8, 2024 | Other filings | SEC |
| 425 | Nov 8, 2024 | Other filings | SEC |
| 425 | Nov 8, 2024 | Other filings | SEC |
| 425 | Nov 8, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 8, 2024 | Material contract | SEC |
| 4 · Change in ownership | Nov 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 5, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 5, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 5, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 5, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 23, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 22, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 22, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 22, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 21, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 21, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 21, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 21, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Oct 11, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 4, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 3, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 3, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 3, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 3, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 22, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 21, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
This page holds 200 of 701 filings. Open Filings
Cap table
Built by 6ix from Kalaris Therapeutics, Inc.’s releases · as of Dec 17, 2025
- Common shares
- 23,804,981
- Fully diluted
- 23,804,981
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 23,804,981 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 23,804,981 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Srinivas Akkaraju Other companies: Alumis Inc. (Founder and Managing Member, Samsara BioCapital · Since at least Jun 27, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 23, 2024); Mineralys Therapeutics, Inc. (Board Member · Since at least Feb 9, 2023); Scholar Rock Holding Corporation (Director · Since at least Jul 26, 2022); Jiya Acquisition Corp (Director · Nov 18, 2020 – Sep 23, 2022 · Past); Aduro Biotech Inc (Director · Oct 5, 2020 – Aug 11, 2023 · Past); Principia Biopharma Inc (Director · Sep 13, 2018 – Sep 18, 2018 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 8, 2017 – Sep 16, 2024 · Past); aTyr Pharma, Inc. (Director · May 6, 2015 – May 9, 2017 · Past); ZS Pharma Inc (Director · Jun 23, 2014 – Dec 17, 2015 · Past); Aravive Inc (Director · Mar 20, 2014 – Dec 2, 2019 · Past); Intercept Pharmaceuticals Inc (Director · Oct 10, 2012 – Nov 8, 2023 · Past); Synageva BioPharma Corp (Director · Nov 2, 2011 – Mar 19, 2012 · Past); Barrier Therapeutics Inc (Director · Jun 6, 2007 – Aug 5, 2008 · Past); Pharmos Corp (Director · Oct 25, 2006 – Jan 15, 2009 · Past); Seagen Inc (Director · Apr 6, 2006 – May 15, 2020 · Past) | Director · Since at least Mar 18, 2025 |
| Shawn Tomasello Other companies: Cabaletta Bio, Inc. (Independent Director, former CCO of Kite Pharma, Inc. · Since at least Jul 21, 2023); 4D Molecular Therapeutics, Inc. (Director · Since at least Dec 10, 2020); Gamida Cell Ltd (Director · Jan 1, 2022 – Jan 31, 2024 · Past); Tcr2 Therapeutics Inc (Director · Feb 3, 2021 – Jun 1, 2023 · Past); Abeona Therapeutics Inc. (Director · Apr 15, 2020 – May 20, 2020 · Past); Principia Biopharma Inc (Director · Aug 29, 2019 – Sep 28, 2020 · Past); UroGen Pharma Ltd. (Director · Jan 1, 2019 – Jun 7, 2021 · Past); Kite Pharma Inc (Chief Commercial Officer · Dec 17, 2015 – Oct 3, 2017 · Past); Diplomat Pharmacy Inc (Director · Oct 6, 2015 – Feb 10, 2020 · Past); Pharmacyclics Inc (Chief Commercial Officer · Aug 18, 2014 – May 26, 2015 · Past) | Director · Mar 29, 2022 – Jun 6, 2024 · Past |
| Ansbert Gadicke Other companies: Cullinan Therapeutics, Inc. (Director · Jan 7, 2021 – Jun 22, 2022 · Past); Iteos Therapeutics Inc (Director · Jul 23, 2020 – Jul 28, 2020 · Past); Tcr2 Therapeutics Inc (Director · Feb 13, 2019 – Jun 1, 2023 · Past); Chiasma Inc (Director · Jul 15, 2015 – Jun 9, 2016 · Past); Verastem, Inc. (Director · Jan 26, 2012 – Mar 6, 2012 · Past); Radius Health, Inc. (Director · May 17, 2011 – Feb 17, 2017 · Past) | Director · Jul 29, 2020 – Jul 28, 2022 · Past |
| Leone Patterson Other companies: Zymeworks Inc. (EVP, Chief Bus & Fin Officer · Since at least Sep 1, 2024); Nkarta, Inc. (Member of Board of Directors · Since at least Jul 9, 2020); Climb Bio, Inc. (Director · Aug 9, 2021 – May 19, 2022 · Past); Tenaya Therapeutics, Inc. (Chief Fin. and Bus. Officer · Jul 29, 2021 – Feb 23, 2024 · Past); Adverum Biotechnologies Inc (President and CFO · Jun 15, 2016 – Feb 16, 2021 · Past); Paratek Pharmaceuticals Inc (Vice President, CFO · Jun 25, 2012 – Oct 30, 2014 · Past) | Director · Since at least Apr 3, 2025 |
| Laurie Keating Other companies: PepGen Inc. (Director · Since at least May 5, 2022); Immuneering Corporation (Director · Since at least Jul 29, 2021); Imago Biosciences Inc (Director · Nov 17, 2021 – Jan 11, 2023 · Past); Alnylam Pharmaceuticals, Inc. (EVP, Chief Legal Officer · Jan 11, 2021 – Aug 5, 2021 · Past); Millennium Pharmaceuticals Inc (SVP and General Counsel · Mar 3, 2006 – May 14, 2008 · Past) | Director · Since at least Jul 6, 2026 |
| David L. Hallal Other companies: Iteos Therapeutics Inc (Director · Since at least Jul 23, 2020); Scholar Rock Holding Corporation (Chairman and Chief Executive Officer · Since at least May 23, 2018); Seer, Inc. (Director · Dec 3, 2020 – Jun 12, 2024 · Past); Alexion Pharmaceuticals Inc (CEO, Director · Feb 23, 2009 – Aug 8, 2016 · Past) | Director · Since at least Jul 29, 2020 |
| Michael Dybbs Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Nkarta, Inc. (Director · Since at least Jul 9, 2020); Sutro Biopharma, Inc. (Member, Board of Directors · Since at least Sep 26, 2018); Dimension Therapeutics (Director · Oct 21, 2015 – Nov 7, 2017 · Past) | Director · Since at least Mar 18, 2025 |
| Vikas Sinha Other companies: Scholar Rock Holding Corporation (Chief Financial Officer · Since at least Apr 27, 2025); Verona Pharma plc (Director · Since at least Jan 1, 2021); BCLS Acquisition Corp (Director · Oct 22, 2020 – Oct 22, 2020 · Past); Alexion Pharmaceuticals Inc (EVP & CFO · Jul 12, 2013 – Aug 8, 2016 · Past) | See Remarks, Director · Jul 29, 2020 – Feb 21, 2025 · Past |
| Jeff Bornstein Other companies: Eos Energy Enterprises, Inc. (Director · Since at least Sep 7, 2022); SpringBig Holdings, Inc. (Director · Feb 11, 2021 – Feb 11, 2021 · Past); GE Aerospace (Vice Chairman · Jul 1, 2013 – Nov 6, 2017 · Past) | Director · Jul 29, 2020 – Jun 6, 2024 · Past |
| Andrew Oxtoby Other companies: Aduro Biotech Inc (Chief Commercial Officer · Feb 15, 2023 – Aug 11, 2023 · Past); Aimmune Therapeutics Inc (Chief Commercial Officer · Jan 22, 2019 – Oct 10, 2020 · Past) | CEO & Director · Since at least Mar 18, 2025 |
All 31 people
| Person | Seat |
|---|---|
| Cintia Piccina Other companies: Autolus Therapeutics plc (Senior Vice President, General Manager US · Since at least Mar 18, 2026); Adaptimmune Therapeutics PLC (Chief Commercial Officer · Jan 31, 2022 – Feb 20, 2025 · Past) | Chief Commercial Officer · Jun 12, 2023 – Jul 3, 2023 · Past |
| Matthew Gall Other companies: Tango Therapeutics, Inc. (Chief Financial Officer · Since at least Apr 15, 2026); Iteos Therapeutics Inc (Chief Financial Officer · Since at least Jul 23, 2020) | Chief Financial Officer · Since at least Nov 3, 2025 |
| Morana Jovan-Embiricos Other companies: Cullinan Therapeutics, Inc. (Director · Jan 7, 2021 – Sep 16, 2021 · Past); Tcr2 Therapeutics Inc (Director · Feb 13, 2019 – Feb 19, 2019 · Past) | Director · Since at least Jul 29, 2020 |
| Agustin Melian Other companies: Forma Therapeutics Holdings Inc (EVP, Research & Development · Jul 11, 2022 – Oct 14, 2022 · Past) | Chief Medical Officer · Jul 29, 2020 – Oct 4, 2021 · Past |
| Ann M Leen Other companies: Marker Therapeutics, Inc. (Chief Scientific Officer · Dec 21, 2018 – Feb 15, 2020 · Past) | Chief Scientific Officer · Jul 29, 2020 – Aug 16, 2022 · Past |
| Anthony Adamis Other companies: EyePoint, Inc. (Director · Jun 23, 2022 – Jun 23, 2024 · Past) | Director · Since at least Nov 8, 2024 |
| Brett R Hagen Other companies: Kineta Inc. (See Remarks · Aug 4, 2016 – Apr 3, 2017 · Past) | Chief Accounting Officer · Since at least Jul 29, 2020 |
| Diana Brainard Other companies: Nektar Therapeutics (Director · Since at least Nov 11, 2021) | Chief Executive Officer, Director · Jul 29, 2020 – Nov 19, 2024 · Past |
| Edward Miller Other companies: Alexion Pharmaceuticals Inc (SVP, Chief Compliance Officer · Sep 9, 2016 – Feb 27, 2017 · Past) | General Counsel · Jul 29, 2020 – Feb 21, 2025 · Past |
| Jeroen B Van Beek Other companies: Tricida Inc (Chief Comm Officer and Sr VP · Jun 27, 2018 – Jul 2, 2018 · Past) | Chief Commercial Officer · Jul 29, 2020 – Nov 16, 2022 · Past |
| John Robert Wilson Other companies: Marker Therapeutics, Inc. (Director · Oct 17, 2018 – Jun 6, 2023 · Past) | Director · Jul 29, 2020 – May 25, 2021 · Past |
| Juan F. Vera Other companies: Marker Therapeutics, Inc. (Chief Executive Officer & Co-Founder, Marker Therapeutics · Since at least Oct 17, 2018) | Director · Jul 29, 2020 – Jun 6, 2024 · Past |
| Mike Dybbs Other companies: Nkarta, Inc. (Director · Since at least Nov 4, 2026) | Director & Co-founder · Since at least Nov 8, 2024 |
| Napoleone Ferrara Other companies: TuHURA Biosciences, Inc. (Director · Apr 30, 2019 – Jun 26, 2020 · Past) | Director & Co-Founder · Since at least Mar 18, 2025 |
| Samir Chandrakant Patel Other companies: IVERIC bio Inc (President, Director · Sep 24, 2013 – Jan 4, 2017 · Past) | Director · Mar 18, 2025 – Apr 10, 2025 · Past |
| Amy O'Leary Vandekop | VP, Corporate Controller · Since at least Jul 27, 2026 |
| Derek N Adams | Director · Mar 1, 2023 – Jun 6, 2024 · Past |
| Ercem Atillasoy | See Remarks · Jul 29, 2020 – Oct 20, 2022 · Past |
| Liisa Bayko | CFO · Since at least Jul 20, 2026 |
| Malcolm Brenner | Director · Jul 29, 2020 – Jun 6, 2024 · Past |
| Matthew Feinsod | Chief Medical Officer · Since at least Mar 18, 2025 |
Log in to ask 6ix AI your own questions about Kalaris Therapeutics, Inc.